AVTX Avalo Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1534120 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-77.1%
TTM net income YoY-11.4%
TTM EPS YoY81.6%
Revenue 3-yr CAGR-56.6%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-15,536.1%
Net margin-7,965.8%
FCF margin-11,123.8%
EBITDA margin-15,497.7%
Returns
ROE-50.1%
ROA-40.9%
ROIC (approx.)—
Asset turnover0.01x
Leverage & solvency
Liabilities / assets11.7%
Debt / equity0.00x
Current ratio19.96x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.40x
Accruals ratio16.2%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $59,000 | $441,000 |
| R&D expense | $50.08M | $24.44M |
| SG&A expense | $22.90M | $17.24M |
| Operating income | -$72.92M | -$68.51M |
| Pretax income | -$78.09M | -$35.02M |
| Income tax | $165,000 | $114,000 |
| Net income | -$78.26M | -$35.13M |
| EBITDA | -$72.58M | -$68.34M |
| EPS (basic) | -5.84 | -7.94 |
| EPS (diluted) | -5.84 | -20.91 |
| Weighted avg. shares (diluted) | 13.40M | 7.50M |
| Balance sheet | ||
| Cash & equivalents | $15.86M | $134.70M |
| Short-term investments | $82.48M | $0 |
| Current assets | $105.29M | $138.89M |
| Goodwill | $10.50M | $10.50M |
| Total assets | $116.46M | $150.73M |
| Current liabilities | $12.94M | $6.96M |
| Total liabilities | $33.41M | $17.70M |
| Shareholders' equity | $83.05M | $133.03M |
| Shares outstanding | 18.51M | 10.47M |
| Cash flow statement | ||
| Operating cash flow | -$51.46M | -$49.06M |
| Capital expenditure | — | $0 |
| Free cash flow | — | -$49.06M |
| Investing cash flow | -$81.72M | $356,000 |
| Financing cash flow | $14.59M | $175.85M |
| Depreciation & amortization | $344,000 | $169,000 |
| Stock-based compensation | $13.62M | $5.85M |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.